Treace John T. - 10 May 2024 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Lisa O. Taylor as Attorney in Fact for John T. Treace
Issuer symbol
TMCI
Transactions as of
10 May 2024
Net transactions value
+$1,370,370
Form type
4
Filing time
13 May 2024, 18:07:34 UTC
Previous filing
12 Mar 2024
Next filing
14 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Purchase $686,880 +150,000 +2.6% $4.58 5,943,095 10 May 2024 Direct F1, F2
transaction TMCI Common Stock Purchase $683,490 +150,000 +2.5% $4.56 6,093,095 13 May 2024 Direct F2, F3
holding TMCI Common Stock 1,605,000 10 May 2024 By spouse F4
holding TMCI Common Stock 1,471,250 10 May 2024 By spouse as co-trustee of a trust F4
holding TMCI Common Stock 1,839,063 10 May 2024 as trustee of a trust F5
holding TMCI Common Stock 408,816 10 May 2024 as co-trustee of a trust F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.4700 to $4.7500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F2 Includes 196,646 restricted stock units
F3 The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3900 to $4.6400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F4 The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
F5 The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.